Loading
NASDAQHealthcareBiotechnology
Latest quote
$11.17
+$0.28 · +2.57%
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Previous close
$11.17
+$0.28 · +2.57%
Pre-market
$11.03
−$0.14 · -1.25%
Sep 15, 5:03 AM ET
Regular session · ET · Market data may be delayed.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Day range
Current $11.17
52-week range
Current $11.17
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
63
Bullish
Risk
49
Elevated Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Day range
Current $11.17
52-week range
Current $11.17
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 75.13M USD | 28.83M USD | 38.03M USD | 485.42M USD | 375.2M USD |
| Cost of goods sold | 28.82M USD | — | — | 66.44M USD | 45.52M USD |
| Gross profit | 46.31M USD | 28.83M USD | 38.03M USD | 418.99M USD | 329.69M USD |
| Research and development | 186.83M USD | 167.26M USD | 175.66M USD | 107.88M USD | 62.06M USD |
| Selling, general, and administrative | 76.58M USD | 85.49M USD | 75.18M USD | 66.76M USD | 48.76M USD |
| Operating expenses | 263.41M USD | 343.6M USD | 275.23M USD | 202.48M USD | 125.27M USD |
| Interest income | 28.33M USD | 38.47M USD | 42.25M USD | 16.08M USD | 3.33M USD |
| Interest expense | — | — | — | 4.05M USD | 5.23M USD |
| Depreciation and amortization | 28.82M USD | 97M USD | 30.89M USD | 33.1M USD | 17.25M USD |
| Operating income | −217.1M USD | −314.77M USD | −237.21M USD | 216.51M USD | 204.41M USD |
| Net income | −146.41M USD | −162.86M USD | −146.4M USD | 158.52M USD | 153.46M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$15.33
37.24% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB19.55M0.19%10.34B USD0.44%$204.6+0.82%
Northern Lights Fund Trust III - Counterpoint Quantitative Equity ETFCPAI12.83M2.85%377.71M USD0.75%$51.61-1.43%
iShares Genomics Immunology and Healthcare ETFIDNA6.39M2.47%256.44M USD0.47%$38.74+1.79%
State Street SPDR Portfolio Developed World ex-US ETFSPDW6.25M0.01%42B USD0.03%$50.92-1.24%
State Street SPDR S&P International Small Cap ETFGWX1.85M0.20%932.67M USD0.40%$45.98-0.91%
Fidelity Nasdaq Composite Index ETFONEQ1.47M0.01%10.75B USD0.21%$103.28-0.48%
Avantis U.S. Equity ETFAVUS705.79K—14.51B USD0.15%$128.84-0.62%
Virtus Biotech Clinical Trials ETFBBC659.5K1.40%46.95M USD0.65%$49.935+1.11%iShares Biotechnology ETFIBBNorthern Lights Fund Trust III - Counterpoint Quantitative Equity ETFCPAIiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Developed World ex-US ETFSPDWState Street SPDR S&P International Small Cap ETFGWXFidelity Nasdaq Composite Index ETFONEQAvantis U.S. Equity ETFAVUSVirtus Biotech Clinical Trials ETFBBCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
